Skip to main content
main-content

01.12.2017 | Correspondence | Ausgabe 1/2017 Open Access

BMC Cancer 1/2017

Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial

Zeitschrift:
BMC Cancer > Ausgabe 1/2017
Autoren:
M. M. Koeneman, A. J. Kruse, L. F. S. Kooreman, A. zur Hausen, A. H. N. Hopman, S. J. S. Sep, T. Van Gorp, B. F. M. Slangen, H. J. van Beekhuizen, A. J. M. van de Sande, C. G. Gerestein, H. W. Nijman, R. F. P. M. Kruitwagen

Abstract

The “TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia” (TOPIC) trial was stopped preliminary, due to lagging inclusions. This study aimed to evaluate the treatment efficacy and clinical applicability of imiquimod 5% cream in high-grade cervical intraepithelial neoplasia (CIN). The lagging inclusions were mainly due to a strong patient preference for either of the two treatment modalities. This prompted us to initiate a new study on the same subject, with a non-randomized, open-label design: the ‘TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC)-3’ study.
Original TOPIC-trial: Medical Ethics Committee approval number METC13231; ClinicalTrials.gov Identifier: NCT02329171, 22 December 2014.
TOPIC-3 study: Medical Ethics Committee approval number METC162025; ClinicalTrials.gov Identifier: NCT02917746, 16 September 2016.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

BMC Cancer 1/2017 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise